NCT07058987Not yet recruiting
Effects of Enhanced External Counterpulsation Combined With Cardiac Rehabilitation in Patients With Atrial Fibrillation
A Prospective Randomized Controlled Study on the Effects of Enhanced External Counterpulsation Combined With Cardiac Rehabilitation on Cardiac Function and Exercise Capacity in Patients With Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 14 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective randomized controlled trial designed to evaluate the effectiveness of enhanced external counterpulsation (EECP) combined with cardiac rehabilitation in patients with atrial fibrillation. The study aims to assess whether this combined intervention can improve cardiac function and exercise capacity compared to standard care alone. Eligible participants will be randomly assigned to receive either the EECP plus cardiac rehabilitation program or routine treatment. Primary outcomes include changes in left ventricular ejection fraction (LVEF) and six-minute walking distance (6MWD). The study will be conducted at Lanzhou University Second Hospital.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 1 Jul 2025
- Start date
- 15 Jul 2025
- Primary completion date
- 31 Jan 2026
- Lead sponsor
- Lanzhou University Second Hospital
- Diseases
- Heart failure, Atrial fibrillation
- NCT number
- NCT07058987
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 15 Jul 2025 to the primary completion date, 31 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Recent acute myocardial infarction, unstable angina, or decompensated heart failure within the past 4 weeks
- Severe peripheral vascular disease or deep vein thrombosis
- Severe pulmonary disease or active infection
- History of bleeding disorders or contraindications to EECP
- Cognitive impairment or psychiatric condition affecting study participation
Lab values
- Severe valvular heart disease or left ventricular ejection fraction \<30%
Other
- Participation in another clinical trial within the past 3 months
Who the study is looking for
- Age between 40 and 80 years
- Diagnosed with persistent or paroxysmal atrial fibrillation, confirmed by ECG or Holter
- Stable medical condition and able to participate in cardiac rehabilitation and EECP therapy
- Provided written informed consent
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lanzhou University Second Hospital Coordinator of this site? Confirm its status | Lanzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.